Absence of TTF-1 Immunoreactivity Can Predict EGFR Wild-Type in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Bosdet, I. [1 ]
Young, S. S. [1 ]
Ali, R. H. [1 ]
McNeil, B. K. [1 ]
Wong, C. [1 ]
Garbutt, K. [1 ]
Karsan, A. [1 ]
Ionescu, D. N. [1 ]
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
来源：
LABORATORY INVESTIGATION | 2012年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1974
引用
收藏
页码：474A / 474A
页数：1
相关论文
共 50 条
  • [31] The efficacy of erlotinib for patients with non-small cell lung cancer with wild type of EGFR mutations
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Tanabe, Tsuyoshi
    Tsushima, Kenji
    Urushihata, Kazuhisa
    Yamamoto, Hiroshi
    Hanaoka, Masayuki
    Kubo, Keishi
    Koyama, Shigeru
    Ooura, Nariaki
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S690 - S690
  • [32] Activity of Pemetrexed on Wild-Type and Unknown Status EGFR Genes with Brain Metastases from Non-Small Cell Lung Cancer
    Fan, Y.
    Yu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2090 - S2090
  • [33] Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, Lecia, V
    Gray, Jhanelle Elaine
    Harb, Wael A.
    Lopez-Chavez, Ariel
    Doebele, Robert C.
    Modiano, Manuel R.
    Jackman, David Michael
    Baggstrom, Maria Quintos
    Atmaca, Akin
    Felip, Enriqueta
    Provencio, Mariano
    Cobo, Manuel
    Adiwijaya, Bambang
    Kuesters, Geoffrey
    Kamoun, Walid S.
    Andreas, Karen
    Pipas, J. Marc
    Santillana, Sergio
    Cho, Byoung Chul
    Park, Keunchil
    Shepherd, Frances A.
    ONCOLOGIST, 2019, 24 (08): : 1095 - 1102
  • [34] Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, L.
    Gray, J.
    Harb, W.
    Doebele, R.
    Modiano, M.
    Jackman, D.
    Baggstrom, M.
    Atmaca, A.
    Felip, E.
    Provencio, M.
    Cobo Dols, M.
    Adiwijaya, B.
    Kuesters, G.
    Kamoun, W.
    Andreas, K.
    Pipas, J.
    Santillana, S.
    Cho, B. C.
    Park, K.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S596 - S596
  • [35] Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
    Peng, Xiao-Xiao
    Yu, Ruoying
    Wu, Xue
    Wu, Shu-Yu
    Pi, Can
    Chen, Zhi-Hong
    Zhang, Xu-Chao
    Gao, Cun-Yi
    Shao, Yang W.
    Liu, Li
    Wu, Yi-Long
    Zhou, Qing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [36] Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis
    Zhan, Ping
    Qian, Qian
    Wan, Benjamin
    Yan, Tristan D.
    Yu, Li-Ke
    TRANSLATIONAL CANCER RESEARCH, 2013, 2 (01) : 25 - 32
  • [37] EGFR mutation in non-small cell lung cancer(NSCLC) in South Croatia
    Mladinov, Suzana
    Skopljanac, Ivan
    Ivcevic, Veljka
    Kuret, Sendi
    Durdov, Meri Glavina
    Mise, Kornelija
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [38] Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer
    Peters, Solange
    Smit, Egbert
    LANCET ONCOLOGY, 2014, 15 (12): : 1289 - 1290
  • [39] Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: A meta-analysis
    Qian, Hai-hua
    Xu, Tian-shu
    Cai, Xiao-qin
    Ji, Tian-li
    Guo, Hai-xia
    CLINICA CHIMICA ACTA, 2015, 451 : 208 - 214
  • [40] Fascin immunoreactivity correlates with tumor grade in non-small cell lung cancer (NSCLC).
    del Rosario, A
    Goncharuk, VN
    Tran, TA
    Sheehan, CE
    Ross, JS
    MODERN PATHOLOGY, 2001, 14 (01) : 218A - 218A
12345